000	00000nam 2200000za 4500
001	9.833635
003	CaOODSP
005	20221107150247
007	cr |||||||||||
008	170310s2017    onc    #ob   f000 0 eng d
020	|a978-0-660-07912-7
040	|aCaOODSP|beng
043	|an-cn---
086	1 |aHP40-176/2017E-PDF
245	00|aNACI literature review for HPV immunization of immunocompromised populations |h[electronic resource].
246	1 |iAt head of title: |aAdvisory Committee review, National Advisory Committee on Immunization (NACI)
260	|aOttawa : |bPublic Health Agency of Canada, |c2017.
300	|a60 p.
500	|aTitle from cover.
500	|aIssued also in HTML format.
500	|aIssued also in French under title: Examen de la documentation du CCNI concernant l'immunisation contre le VPH des populations immunodéprimées.
504	|aIncludes bibliographical references.
520	|a"Immunocompromised populations are at increased risk for HPV infection and for developing HPV-associated cancers. However, additional clarity is required surrounding the immunogenicity and safety outcomes of HPV immunization for immunocompromised populations. To address this information gap, a research question was developed by the National Advisory Committee on Immunization (NACI) human papillomavirus (HPV) Working Group and used to guide a literature review"--Executive Summary, p. 5.
692	07|2gccst|aImmunization
692	07|2gccst|aInfectious diseases
692	07|2gccst|aResearch
710	2 |aPublic Health Agency of Canada. |bInfectious Disease Prevention and Control Branch.
775	08|tExamen de la documentation du CCNI concernant l’immunisation contre le VPH des populations immunodéprimées |w(CaOODSP)9.833636
856	40|qPDF|s1.21 MB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-176-2017-eng.pdf
856	4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/healthy-living/literature-review-human-papillomavirus-immunization-immunocompromised-populations.html
986	|aPub.: 160350